99. Chronic intestinal pseudo-obstruction Clinical trials / Disease details

Clinical trials : 4 / Drugs : 9 - (DrugBank : 2) / Drug target gene : 1 - Drug target pathways : 4

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04118699 (ClinicalTrials.gov)	December 25, 2019	23/9/2019	Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial	Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Single Center, Randomized, Placebo Controlled, Double-blind Phase 2 Trial	Chronic Intestinal Pseudo-obstruction	Drug: Rifaximin oral tablet;Drug: Placebo oral tablet	Yokohama City University	ASKA Pharmaceutical Co., Ltd.	Active, not recruiting	20 Years	74 Years	All	12	Phase 2	Japan
2	JPRN-jRCT2031190137	25/12/2019	20/11/2019	Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial	Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial	Chronic Intestinal Pseudo-obstruction CIPO, abdominal bloating	Two tablets of the investigational product per dosing (400 mg of rifaximin) or the placebo are orally administered 3 times daily for 4 weeks.	Ohkubo Hidenori	NULL	Not Recruiting	>= 20age old	< 75age old	Both	12	Phase 2	Japan